What is the treatment for von Willebrand disease?

Von Willebrand disease (vWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor, a protein essential for platelet adhesion and aggregation. The treatment for this condition focuses on managing bleeding episodes and improving the function of platelets.

Desmopressin acetate, commonly known as DDAVP, is the correct treatment for von Willebrand disease. This medication works by stimulating the release of von Willebrand factor from endothelial cells, thereby increasing its levels in the bloodstream. This helps enhance platelet function and reduces bleeding risk. DDAVP is particularly effective in patients with type 1 vWD and some cases of type 2 vWD, as it addresses the underlying deficiency of the von Willebrand factor.

While other treatment options are available for different bleeding disorders, they do not specifically address the issues associated with von Willebrand disease. Factor VII is not a treatment for vWD; it is used more for hemophilia. Warfarin is an anticoagulant that could increase bleeding risk, which is counterproductive for a patient with a bleeding disorder. Platelet transfusions may be considered in severe cases, but they do not rectify the underlying von Willebrand factor deficiency, making DDAVP the most appropriate choice